.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD02_Ceftazidime.Ceftazidime .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD02_Ceftazidime.Ceftazidime| name: | Ceftazidime |
| ATC code: | J01DD02 | route: | intravenous |
| n-compartments | 2 |
Ceftazidime is a third-generation cephalosporin antibiotic used to treat a wide range of bacterial infections, including serious infections such as pneumonia, urinary tract infections, and sepsis. It is particularly effective against Gram-negative bacteria and is commonly used in hospital settings. Ceftazidime is approved and widely used today.
Pharmacokinetic parameters reported for healthy adult volunteers after a single intravenous dose.
Zhanel, GG, et al., & Karlowsky, JA (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs 79(3) 271–289. DOI:10.1007/s40265-019-1055-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30712199
Wang, H, et al., & Zhao, Z (2018). Population Pharmacokinetics and Dosing Simulations of Ceftazidime in Chinese Neonates. Journal of pharmaceutical sciences 107(5) 1416–1422. DOI:10.1016/j.xphs.2017.12.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29274818
Cojutti, PG, et al., & Pea, F (2024). An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients. The Journal of antimicrobial chemotherapy 79(11) 2801–2808. DOI:10.1093/jac/dkae290 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39159014